177 filings
Page 7 of 9
6-K
MDNAF
Medicenna Therapeutics Corp.
27 Oct 21
Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States
8:22am
6-K
MDNAF
Medicenna Therapeutics Corp.
7 Oct 21
Medicenna Presents MDNA11 Data from IND-Enabling Studies at the AACR-NCI-EORTC Conference
9:10am
6-K
MDNAF
Medicenna Therapeutics Corp.
23 Sep 21
Medicenna Appoints Dr. John H. Sampson to its Board of Directors
5:28pm
6-K
MDNAF
Medicenna Therapeutics Corp.
22 Sep 21
Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit
10:29am
6-K
MDNAF
Medicenna Therapeutics Corp.
20 Sep 21
Medicenna Announces Issuance of U.S. Patent Providing Added Intellectual Property Protection for its MDNA11 Program
8:16am
6-K
MDNAF
Medicenna Therapeutics Corp.
14 Sep 21
Current report (foreign)
8:32am
6-K
MDNAF
Medicenna Therapeutics Corp.
9 Sep 21
Medicenna Therapeutics to Present at Upcoming September Investor Conferences
9:05am
6-K
MDNAF
Medicenna Therapeutics Corp.
1 Sep 21
Current report (foreign)
8:00am
6-K
MDNAF
Medicenna Therapeutics Corp.
13 Aug 21
Interim condensed consolidated financial statements of
7:10am
6-K
MDNAF
Medicenna Therapeutics Corp.
4 Aug 21
Current report (foreign)
9:20am
6-K
MDNAF
Medicenna Therapeutics Corp.
27 Jul 21
Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference
10:49am
6-K
MDNAF
Medicenna Therapeutics Corp.
14 Jul 21
Current report (foreign)
9:41am
6-K
MDNAF
Medicenna Therapeutics Corp.
23 Jun 21
Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11
9:15am
40-F
2021 FY
MDNAF
Medicenna Therapeutics Corp.
28 May 21
Annual report (Canada)
12:12pm
6-K
MDNAF
Medicenna Therapeutics Corp.
28 May 21
Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights
7:40am
6-K
MDNAF
Medicenna Therapeutics Corp.
20 May 21
Current report (foreign)
9:10am
6-K
MDNAF
Medicenna Therapeutics Corp.
12 May 21
Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer
9:10am
6-K
MDNAF
Medicenna Therapeutics Corp.
7 May 21
Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma
10:04am
6-K
MDNAF
Medicenna Therapeutics Corp.
21 Apr 21
Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer
9:56am
6-K
MDNAF
Medicenna Therapeutics Corp.
14 Apr 21
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference
9:05am